{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:23:44Z","timestamp":1790310224400,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chronic and inappropriate benzodiazepine (BDZ) prescription and intake represent an important health and social concern worldwide. The aim of our study was to investigate the safety and efficacy of P. incarnata L., herba in reducing BDZ misuse in a real-world population of depressed and anxious patients in a long-term treatment with BDZs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Over an 18-month period (from July 2021 to December 2022), we previously conducted a retrospective and naturalistic study on euthymic outpatients with a diagnosis of anxiety or depression and chronically taking BDZs. In this study we contacted patients 12 months after their enrollment in the previous study to assess their disease status and their BDZs and P. incarnata intake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our findings support the effectiveness of a dry extract of P. incarnata L., herba, as an add-on treatment during BDZ tapering in patients with anxiety or depression. We confirmed this effect to be sustained over time, and P. incarnata showed to be easily discontinued with no rebound, withdrawal or psychological dependence effect. The absence of side effects and adverse events confirmed the safety of P. incarnata in a real-world population. Personality disorders confirmed to be a relevant risk factor for maintaining addictive behavior, even when symptoms associated to withdrawal seem to be not particularly relevant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>We confirmed the possible effectiveness of P. incarnata as an add-on treatment in BDZ reduction. Further studies may be helpful to better investigate the promising properties of P. incarnata in the management of relevant clinical issues, such as anxiety disorders and addiction, that are classically known to benefit from GABAergic treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2024.1471083","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:27:22Z","timestamp":1728016042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Passiflora incarnata L., herba, in benzodiazepine tapering: long-term safety and efficacy in a real-world setting"],"prefix":"10.3389","volume":"15","author":[{"given":"Matteo","family":"Carminati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Tondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"B1","unstructured":"FDA Srug Safety Communication on Benzodiazepine, 9\/23\/2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"Luscher","year":"2011","journal-title":"Mol Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.5.433","article-title":"Extent and appropriateness of benzodiazepine use. Results from an elderly urban community","volume":"173","author":"Taylor","year":"1998","journal-title":"Br J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr Serv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: uses, dangers, and clinical considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint14030053","article-title":"Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14165","article-title":"Misuse of benzodiazepines: Prevalence and impact in an inpatient population with psychiatric disorders","volume":"86","author":"Panes","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20451253221082386","DOI":"10.1177\/20451253221082386","article-title":"Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey","volume":"12","author":"Reid Finlayson","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: how can it be reduced","volume":"77","author":"Lader","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"B10","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","author":"O'Brien","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/fampra\/cmac037","article-title":"Correction to: Discontinuation of chronic benzodiazepine use in primary care: a nonrandomized intervention","volume":"39","author":"Fernandes","year":"2022","journal-title":"Fam Pract"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-32-9705-0_19","article-title":"Current and novel psychopharmacological drugs for anxiety disorders","volume":"1191","author":"Bandelow","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD010677","DOI":"10.1002\/14651858.CD010677.pub2","article-title":"Benzodiazepines versus placebo for panic disorder in adults","volume":"3","author":"Breilmann","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1429403","article-title":"Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines","volume":"17","author":"Quagliato","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-32-9705-0_20","article-title":"Role of benzodiazepines in anxiety disorders","volume":"1191","author":"Balon","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmh309","article-title":"Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics","volume":"21","author":"Zandstra","year":"2004","journal-title":"Fam Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3109\/08039481003624173","article-title":"Benzodiazepine tapering: a prospective study","volume":"64","author":"Vikander","year":"2010","journal-title":"Nord J Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2257-8","article-title":"A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people","volume":"73","author":"Reeve","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000525988","article-title":"Cognitive functioning in long-term benzodiazepine users","volume":"28","author":"Zetsen","year":"2022","journal-title":"Eur Addict Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.07.051","article-title":"Factors associated with the long-term use of benzodiazepine receptor agonists as hypnotics among patients with major depressive disorder and comorbid insomnia","volume":"178","author":"Habukawa","year":"2024","journal-title":"J Psychiatr Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48557","article-title":"Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy","volume":"6","author":"Maust","year":"2023","journal-title":"JAMA network Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22057","article-title":"Benzodiazepine drug use and cancer risk: a dose-response meta analysis of prospective cohort studies","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000316","article-title":"Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology","volume":"35","author":"Lim","year":"2020","journal-title":"Int Clin Psychopharmacol"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1017\/9781108975292","author":"Stahl","year":"2021","journal-title":"Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (5th ed)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15816","article-title":"Benzodiazepine misuse: an epidemic within a pandemic","volume":"13","author":"Sarangi","year":"2021","journal-title":"Cureus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.1150","article-title":"Complex persistent benzodiazepine dependence-when benzodiazepine deprescribing goes awry","volume":"79","author":"Peng","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12174","article-title":"Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States","volume":"79","author":"Blanco","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.05.020","article-title":"Benzodiazepine misuse among adults receiving psychiatric treatment","volume":"128","author":"McHugh","year":"2020","journal-title":"J Psychiatr Res"},{"key":"B31","article-title":"GABA(B) receptors: anxiety and mood disorders","volume":"52","author":"Felice","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2146\/ajhp160712","article-title":"Pregabalin as adjunctive therapy in benzodiazepine discontinuation","volume":"75","author":"Caniff","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.12.004","article-title":"Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice","volume":"27","author":"Bobes","year":"2012","journal-title":"Eur Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2015.1125493","article-title":"Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients","volume":"42","author":"Mariani","year":"2016","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B35","doi-asserted-by":"publisher","first-page":"CD011481","DOI":"10.1002\/14651858.CD011481.pub2","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199912002-00003","article-title":"Pharmacologic strategies for discontinuing benzodiazepine treatment","volume":"19","author":"Rickels","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92861-0","article-title":"Benzodiazepine withdrawal symptoms and propranolol","volume":"1","author":"Tyrer","year":"1981","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246214","article-title":"Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome","volume":"117","author":"Schweizer","year":"1995","journal-title":"Psychopharmacol (Berl)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199804000-00004","article-title":"A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation","volume":"18","author":"Romach","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.168.4.457","article-title":"A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms","volume":"168","author":"Tyrer","year":"1996","journal-title":"Br J Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198702000-00003","article-title":"A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms","volume":"7","author":"Lader","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.12.1590","article-title":"Failure of buspirone to manage benzodiazepine withdrawal","volume":"143","author":"Schweizer","year":"1986","journal-title":"Am J Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.12.1973","article-title":"Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy","volume":"157","author":"Rickels","year":"2000","journal-title":"Am J Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.drugalcdep.2018.04.028","article-title":"Review: Adjunctive pharmacologic approaches for benzodiazepine tapers","volume":"189","author":"Welsh","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002130050798","article-title":"Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome","volume":"141","author":"Rickels","year":"1999","journal-title":"Psychopharmacol (Berl)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.11.023","article-title":"Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality","volume":"149","author":"Berge","year":"2022","journal-title":"J Psychiatr Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2515690X20967323","DOI":"10.1177\/2515690X20967323","article-title":"Valerian root in treating sleep problems and associated disorders-A systematic review and meta-analysis","volume":"25","author":"Shinjyo","year":"2020","journal-title":"J Evid Based Integr Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123894","article-title":"Passiflora incarnata in neuropsychiatric disorders-A systematic review","volume":"12","author":"Janda","year":"2020","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABA(A) receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.v25.6","article-title":"Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L","volume":"25","author":"Appel","year":"2011","journal-title":"Phytother Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020530","article-title":"Herbal remedies and their possible effect on the GABAergic system and sleep","volume":"13","author":"Bruni","year":"2021","journal-title":"Nutrients"},{"key":"B52","article-title":"Add-On Treatment with Passiflora incarnata L., herba, during Benzodiazepine Tapering in Patients with Depression and Anxiety: A Real-World Study","volume":"16","author":"Zanardi","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00330-5","article-title":"The long-term outcome of a benzodiazepine discontinuation programme in depressed outpatients","volume":"70","author":"Couvee","year":"2002","journal-title":"J Affect Disord"},{"key":"B54","article-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the hamilton depression rating scale","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J Affect Disord"},{"key":"B56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/occmed\/kqv054","article-title":"Hamilton rating scale for anxiety (HAM-A)","volume":"65","author":"Thompson","year":"2015","journal-title":"Occup Med (Lond)"},{"key":"B57","volume-title":"JASP (Version 0.17.1)","year":"2023"},{"key":"B58","unstructured":"Microsoft Exce2018"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.06.001","article-title":"Hospital initiation of benzodiazepines and Z-drugs in older adults and discontinuation in primary care","volume":"18","author":"Coll","year":"2022","journal-title":"Res Soc Adm Pharm"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dcb2f3","article-title":"Tapering clonazepam in patients with panic disorder after at least 3 years of treatment","volume":"30","author":"Nardi","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2006.11.021","article-title":"Possible involvement of GABA A-benzodiazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice","volume":"111","author":"Lolli","year":"2007","journal-title":"J Ethnopharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.07.003","article-title":"Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders","volume":"110","author":"Kumar","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"B63","article-title":"Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic","volume":"6","author":"Dhawan","year":"2003","journal-title":"J Pharm Pharm Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2001.00366.x","article-title":"Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial","volume":"26","author":"Akhondzadeh","year":"2001","journal-title":"J Clin Pharm Ther"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1471083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:27:27Z","timestamp":1728016047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1471083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":64,"alternative-id":["10.3389\/fpsyt.2024.1471083"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1471083","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"article-number":"1471083"}}